Cellyrix Therapeutics

Company Overview

Snapshot

Founded in December 2024 by Eran Kotler, Avishai Gavish, and Mordechai Applebaum, Cellyrix Therapeutics operates with 1–10 employees. The company has secured Pre-Seed funding in December 2024 from AION Labs, highlighting early investor confidence in its innovative approach to cancer treatment.

Business overview

Cellyrix Therapeutics is pioneering a new modality in cancer treatment by addressing tumor heterogeneity, a key challenge in therapy resistance, metastasis, and relapse. Leveraging breakthroughs in single-cell sequencing and artificial intelligence, the company develops innovative cancer treatments. Operating within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology and Drugs Discovery & Development, Cellyrix serves the healthcare and life sciences industries, focusing on pharmaceuticals.

Company Intelligence Q&A

What is Cellyrix Therapeutics' primary focus?

Cellyrix Therapeutics is focused on introducing a new modality into cancer treatment by targeting tumor heterogeneity, which is a fundamental aspect of cancer contributing to therapy resistance, metastasis, and relapse.

When was Cellyrix Therapeutics founded?

Cellyrix Therapeutics was founded in December 2024.

Who are the founders of Cellyrix Therapeutics?

The founders of Cellyrix Therapeutics are Eran Kotler, Avishai Gavish, and Mordechai Applebaum.

What technologies does Cellyrix Therapeutics leverage?

Cellyrix Therapeutics leverages breakthroughs in single-cell sequencing and artificial intelligence to unlock insights into intra-tumor heterogeneity and develop innovative cancer treatments.

Which investor participated in Cellyrix Therapeutics' Pre-Seed funding round?

In December 2024, Cellyrix Therapeutics secured Pre-Seed funding from AION Labs.